A multi-centre long term follow-up study to assess the durability of sustained virologic response in alisporivir treated chronic hepatitis C patients

Trial Profile

A multi-centre long term follow-up study to assess the durability of sustained virologic response in alisporivir treated chronic hepatitis C patients

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2016

At a glance

  • Drugs Alisporivir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Novartis Pharma A.G.
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 May 2015 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
    • 18 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top